Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

04/03/1	3			
Name	Name of entity			
buyN	lyplace.com.au Limited			
ABN	00 004 504			
68 13	32 204 561			
We (	the entity) give ASX the following	g information.		
	rt 1 - All issues nust complete the relevant sections (att	ach sheets if there is not enough space).		
1	*Class of *securities issued or to be issued	Fully paid ordinary shares		
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	150,000		
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares		

<sup>+</sup> See chapter 19 for defined terms.

4 Yes - the shares issued will rank equally in all Do the \*securities rank equally respect with all ordinary shares currently on in all respects from the +issue issue. date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend. (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next distribution dividend, interest payment Issue price or consideration \$0.25 (25 cents) per share 5 Purpose of the issue Exercise of options. 6 (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 25 November 2016 6b The date the security holder resolution under rule 7.1A was passed Nil 6c Number of +securities issued without security holder approval under rule 7.1 Nil 6d Number of \*securities issued with security holder approval under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of +securities issued under an exception in rule 7.2	150,000 fully paid ordina	ary shares
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
_			
7	*Issue dates	13 January 2017	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	+01
0	Ni silas and all all and a		+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	37,336,706 15,520,488	Ordinary shares  Fully paid ordinary shares – subject to 12 months escrow
		10,886,560	Fully paid ordinary shares – subject to 24 months escrow

<sup>+</sup> See chapter 19 for defined terms.

9	Number and +class of all
	*securities not quoted on ASX
	(including the *securities in
	section 2 if applicable)

Number	+Class
2,500,000	Director options exercisable at \$0.25 on or before 28 February 2021
2,500,000	Director options exercisable at \$0.30 on or before 28 February 2021
2,500,000	Director options exercisable at \$0.35 on or before 28 February 2021
1,600,000	Employee options exercisable at \$0.25 on or before 28 February 2021
1,750,000	Employee options exercisable at \$0.30 on or before 28 February 2021
1,750,000	Employee options exercisable at \$0.35 on or before 28 February 2021
625,000	Options exercisable at \$0.25 on or before 28 February 2021
625,000	Options exercisable at \$0.30 on or before 28 February 2021
625,000	Options exercisable at \$0.35 on or before 28 February 2021
300,000	Employee options exercisable at \$0.25 on or before 9 August 2021
300,000	Employee options exercisable at \$0.30 on or before 9 August 2021
300,000	Employee options exercisable at \$0.35 on or before 9 August 2021

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9	Number	and	+class	of	all
	+securities	s not	quoted	on	ASX
	(including	the	+secu	rities	in :
	section 2	if app	licable)		

2,500,000	Performance Rights Tranche 1, expiring 30 June 2019 - subject to 24 month escrow
2,500,000	Performance Rights Tranche 2, expiring 30 June 2019 – subject to 24 month escrow
2,500,000	Performance Rights Tranche 3, expiring 30 June 2019 – subject to 24 month escrow
2,050,000	Performance Rights Tranche 1, expiring 30 June 2019
2,050,000	Performance Rights Tranche 2, expiring 30 June 2019
2,050,000	Performance Rights Tranche 3, expiring 30 June 2019
625,000	Performance Rights (B) Tranche 1, expiring 30 June 2019 - subject to 24 month escrow
625,000 625,000	Performance Rights (B) Tranche 2, expiring 30 June 2019 – subject to 24 month escrow
	Performance Rights (B) Tranche 3, expiring 30 June 2019 – subject to 24 month escrow

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

/A

<sup>+</sup> See chapter 19 for defined terms.

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	*Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

25 If the issue is contingent on security holders' approval, the date of the meeting  26 Date entitlement and acceptance form and offer documents will be sent to persons entitled  27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders  28 Date rights trading will begin (if applicable)  29 Date rights trading will end (if applicable)  30 How do security holders sell their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?			
acceptance form and offer documents will be sent to persons entitled  27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders  28 Date rights trading will begin (if applicable)  29 Date rights trading will end (if applicable)  N/A  30 How do security holders sell their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?	25	security holders' approval, the	N/A
and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders  28 Date rights trading will begin (if applicable)  29 Date rights trading will end (if applicable)  N/A  30 How do security holders sell their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  N/A  N/A  N/A	26	acceptance form and offer documents will be sent to	N/A
applicable)  29 Date rights trading will end (if applicable)  30 How do security holders sell their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?	27	and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	N/A
applicable)  30 How do security holders sell their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?	28		N/A
their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?	29		N/A
of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?	30	their entitlements in full through	N/A
of their entitlements (except by sale through a broker)?	31	of their entitlements through a broker and accept for the	N/A
33 *Issue date N/A	32	of their entitlements (except by	N/A
	33	†Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of *securities  tick one)	
(a)	*Securities described in Part 1	
(b)	All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully p employee incentive share securities when restriction ends, securities issued on expiry or conversion convertible securities	

## Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Entit	ties that have ticked box 3	4(b)	
38	Number of *securities for which *quotation is sought	N/A	
39	*Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A	
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)	N/A	
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number N/A	+Class N/A

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at the 
  time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

MELANIE LEYDIN Company Secretary

13 January 2017

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
<ul> <li>Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	-	
<ul> <li>Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	-	
<ul> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul>	-	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the	29 February 2016 – Public offer – 20,055,454	
subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of	29 February 2016 – Director repayment shares – 1,800,000	
securities on different dates as separate line items	29 February 2016 – Unrelated party vendor shares – 14,738,437	
	29 February 2016 – Related party vendor and promoter's shares – 10,886,560	
	22 December 2016 – Right Issue – 8,451,192	
	13 January 2017 – Exercise of options – 150,000	
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	-	
"A"	63,743,754	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	9,561,563
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	4 March 2016 – 1,875,000 unlisted options
Under an exception in rule 7.2	4 March 2016 – 1,875,000 performance rights (B)
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	3,750,000
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15	9,561,563
Note: number must be same as shown in Step 2	
Subtract "C"	3,750,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	5,811,563
	Note: this is the remaining placement capacity under rule 7.1

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A"  Note: number must be same as shown in Step 1 of Part 1	63,743,754
Step 2: Calculate 10% of "A"	
"D"	0.10  Note: this value cannot be changed
<b>Multiply</b> "A" by 0.10	6,374,375
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
<ul> <li>Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	-
"E"	-
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	6,374,375
Note: number must be same as shown in Step 2	
Subtract "E"	-
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	6,374,375
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.